Kobayashi Pharmaceutical Co., Ltd.
Notice Regarding Executive Personnel Changes Following Transition to a Company with an Audit and Supervisory Committee
Subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, the company will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee and has decided on new executive candidates.
Key Figures
- Number of Director Candidates Not Serving as Audit and Supervisory Committee Members: 8 members
- Number of Director Candidates Serving as Audit and Supervisory Committee Members: 3 members
- Number of Auditors Scheduled to Retire: 4 members
AI要約
Overview of Executive Personnel Changes
Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee, subject to approval at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026. In line with this, at the Board of Directors meeting on February 10, 2026, the director candidates to be proposed to the Annual General Meeting of Shareholders were finalized. The candidates consist of eight directors not serving as Audit and Supervisory Committee members and three directors who will serve as Audit and Supervisory Committee members. Four auditors are scheduled to retire.
Skills Matrix of Director Candidates and Expectations for Enhancing Corporate Value
The director candidates possess diverse skills across corporate management, global business, organizational management, ESG and sustainability, finance and accounting, legal and risk management, and research & development. This aims to enhance corporate value and establish an effective supervisory function. Through optimizing the composition of executives, governance is expected to be strengthened as a company with an Audit and Supervisory Committee.
